# Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

> **NCT02347111** · PHASE4 · RECRUITING · sponsor: **University of Illinois at Chicago** · enrollment: 162 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Flecainide
- **DRUG:** Sotalol

## Key facts

- **NCT ID:** NCT02347111
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-31
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2025-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02347111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02347111, "Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02347111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*